• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN
Ted White, Verrica CEO
September 21, 2021 07:10 AM EDT
FDA+
Manufacturing

Ver­ri­ca hits an­oth­er bump in the road with CMO re­lat­ed let­ter from FDA

Josh Sullivan

The FDA has re­ject­ed Ver­ri­ca’s new drug ap­pli­ca­tion for VP-102 again, with the com­pa­ny pin­ning the CRL on prob­lems at a CMO that it was …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

more like this

  • Eu­ro­pean reg­u­la­tors lift re­stric­tion on Val­ne­va’s chikun­gun­ya vac­cine July 11, 2025
  • FDA kicks off lat­est reau­tho­riza­tion of gener­ic drug user fee leg­is­la­tion July 11, 2025
  • FDA's Makary calls for ty­ing fast-re­view vouch­ers to low­er US prices, with­out specifics July 11, 2025
TRENDING NOW

FDA de­clines to ap­prove Ul­tragenyx's San­fil­ip­po gene ther­a­py, cit­ing man­u­fac­tur­ing is­sues

23andMe files for bank­rupt­cy, CEO Wo­j­ci­c­ki steps down

Re­gen­eron plans to buy 23andMe for $256M

23and­Me's CEO files plan to take com­pa­ny pri­vate

FDA chief calls for low­er user fees as ne­go­ti­a­tions be­gin for eighth round of PDU­FA

As­traZeneca posts a piv­otal tri­al win for blood pres­sure pill be­hind $1.3B deal

Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times